NRXP — NRX Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $73.41m
- $65.61m
- $1.23m
Annual cashflow statement for NRX Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -93.1 | -39.8 | -30.1 | -25.1 | -28.6 |
| Depreciation | |||||
| Non-Cash Items | 60.3 | -0.704 | 3.32 | 9.19 | 13 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.9 | 0.699 | 5.16 | 5.29 | 1.41 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -37.7 | -39.8 | -21.7 | -10.6 | -14.1 |
| Capital Expenditures | -0.007 | -0.01 | -0.003 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -2.81 |
| Acquisition of Business | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.007 | -0.01 | -0.003 | 0 | -2.81 |
| Financing Cash Flow Items | 11.1 | 0 | 0 | 3.39 | 2.42 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 63.5 | 32.2 | 6.2 | 7.49 | 23.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 25.7 | -7.55 | -15.5 | -3.15 | 6.35 |